

SYNEKTIK SA

Fact Sheet



- Company profile**
- Integrator of innovative solutions for medicine
 - Leading supplier of **advanced medical technologies**
 - Largest manufacturer and supplier of **radiopharmaceuticals** in Poland
 - Research and Development Centre** focused on developing innovative particles and radiopharmaceutical products



24
YEARS
OF BUSINESS



14
YEARS SINCE
GOING PUBLIC



200+
EMPLOYEES



36%
REVENUE CAGR
OVER LAST 5 YEARS

Main shareholders

Shareholder	# shares	% of votes
Melhus Company Ltd*	2 047 380	24.00%
Książek Holding Sp. z o.o.	1 376 143	16.13%
Nationale-Nederlanden PTE	724 755	8.55%

*The entity controlled by Cezary Kozanecki

Stock data (WSE)


WSE ticker	SNT	EPS* (PLN)	12.21
Indices	WIG, sWIG40	DPS (PLN)	8.25
mCAP (m PLN)	1.906	P/E*	18.3
Free-float (m PLN)	1.141	EV/EBITDA*	12.1

Capitalisation and market ratios are calculated at the share price as of 28 February 2025, with adjusted EBITDA and net profit, on a last 12 months (LTM) basis


Share price performance (PLN)



Sales segmentation



Sales split by regions




SYNEKTIK SA

Fact Sheet




Selected financial data (PLN million)


Consolidated revenue



Recurring EBITDA



Recurring net result



Data and financial ratios (PLN million)

	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	FY 2023	FY 2022
Revenues:	203.1	141.1	124.0	87.7	271.3	135.7	101.7	65.7	143.8	624.1	446.9
Medical equipment, IT solutions	191.1	128.4	114.2	75.1	261.4	125.7	94.0	55.0	136.2	579.0	410.4
Radiopharmaceuticals	12.1	12.7	9.8	12.6	9.9	10.0	8.1	10.8	7.3	45.0	36.5
EBIT	41.5	24.3	20.7	16.6	45.4	23.0	17.0	3.2	24.6	106.9	67.9
Net financials	-0.7	-0.1	-0.2	-1.5	-1.8	-3.4	0.3	1.7	-0.7	-3.8	-2.2
Pre-tax profit	41.0	24.3	20.7	15.3	43.6	19.6	17.3	4.9	23.9	103.9	65.7
Net profit	33.1	18.9	16.7	12.2	34.7	15.8	13.5	4.0	19.1	82.6	52.5
Recurring EBITDA	51.0	34.5	32.4	25.5	53.1	31.7	24.9	10.9	29.8	145.6	97.3
	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	FY 2023	FY 2022
Not-current assets, incl.:	165.9	163.0	147.6	143.0	138.3	131.3	130.8	123.6	127.1	163.0	131.3
Property, plant and equipment	65.1	59.5	50.5	47.1	45.8	37.7	38.5	39.5	35.0	59.5	37.7
Other intangible assets	40.6	42.2	44.4	45.6	47.6	50.3	51.7	54.1	55.3	42.2	50.3
Current assets, incl.:	319.1	212.3	202.9	179.6	259.3	168.6	129.1	116.7	107.1	212.3	168.6
Inventories	40.6	12.7	27.2	31.6	17.6	21.3	28.3	28.5	14.5	12.7	21.3
Trade receivables	86.8	111.7	95.2	71.5	62.6	79.7	75.7	57.5	59.9	111.7	79.7
Cash	187.5	84.3	76.7	71.6	173.9	62.7	20.7	26.0	29.2	84.3	62.7
Equity	223.1	190.0	171.4	154.4	168.9	134.2	117.9	105.5	106.5	190.0	134.2
Non-current liabilities:	52.6	50.6	42.1	42.1	38.9	47.5	50.2	42.4	40.5	50.6	47.5
Lease liabilities	15.6	19.2	13.2	13.6	10.9	13.8	13.4	8.2	8.4	19.2	13.8
Trade and other liabilities	6.1	5.6	4.2	4.2	4.1	11.6	10.5	11.1	10.8	5.6	11.6
Current liabilities, including:	209.3	134.7	137.1	126.1	189.8	118.2	91.8	92.4	87.1	134.7	118.2
Liabilities under bank loans and borrowings	-	-	-	-	0.7	1.3	9.0	4.6	2.7	-	1.3
Lease liabilities	4.9	5.3	4.0	4.0	3.4	3.6	3.1	2.7	2.6	5.3	3.6
Trade and other liabilities	164.9	90.8	89.2	84.0	145.8	90.8	67.0	75.4	56.4	90.8	90.8
Net debt	-166.9	-59.8	-59.5	-54.0	-158.8	-43.9	4.8	-10.4	-14.8	-59.8	-43.9

SYNEKTIK SA

ul. Józefa Piłsa Dziekońskiego 3
00-728 Warsaw, Poland

www.synektik.com.pl
synektik@synektik.com.pl

Investor Relations

Błażej Dowgielski | +48 692 823 744
b.dowgielski@makmedia.pl